Wall Street rebounds as tech stocks surge, with the S&P 500 up 0.5% amid easing trade tensions and strong corporate earnings.

Robert F. Kennedy Jr.'s nomination for US health secretary advances with crucial Republican support, despite controversy over ...

In a report released yesterday, Umer Raffat from Evercore ISI maintained a Buy rating on Merck & Company (MRK – Research Report). The company’s shares closed yesterday at $89.67. Leverage the ...

Bernstein analyst Courtney Breen maintained a Hold rating on Merck & Company (MRK – Research Report) yesterday and set a price target of $110.00. The company’s shares closed yesterday at $89.67.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

In October, Merck took up an option on the personalised RNA-based cancer vaccine with an upfront payment of $250 million as part of a collaboration first agreed in 2016 and expanded in 2018.

Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices ...

There is no Morningstar’s Analysis data available. We sell different types of products and services to both investment professionals and individual investors. These products and services are ...

Apple's Advanced Data Protection for iCloud feature uses end-to-end encryption to provide the highest level of cloud data security that Apple offers. Here's everything you need to know about ...

SEC Filings provided by EDGAR Online, Inc.